Filing Details
- Accession Number:
- 0001140361-11-005845
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-02-03 11:43:53
- Reporting Period:
- 2011-02-01
- Filing Date:
- 2011-02-03
- Accepted Time:
- 2011-02-03 11:43:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1350577 | Ali Naqui | One Idexx Drive Westbrook ME 04092 | Corporate Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-02-01 | 3,678 | $28.66 | 19,686 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2011-02-01 | 3,230 | $25.45 | 22,916 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-02-01 | 1,678 | $72.24 | 21,238 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2011-02-01 | 3,230 | $72.21 | 18,008 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (right to buy) | Disposition | 2011-02-01 | 3,678 | $0.00 | 3,678 | $28.66 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2011-02-01 | 3,230 | $0.00 | 3,230 | $25.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2015-02-02 | No | 4 | M | Direct | |
| 0 | 2014-02-04 | No | 4 | M | Direct |
Footnotes
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $72.22 to $72.2746, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $72.21 to $72.235, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 1,358 shares on 2/3/2009 and the remaining 2,320 shares on 2/3/2010.
- Grant of options to buy shares of common stock becomes exercisable as to 2,400 shares on 2/5/2005, 2/5/2006 and 2/5/2007, and the remaining 1,030 shares on 2/5/2008.
Billionaire Hedge Funds
